Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00386971 · ClinicalTrials.gov registry record · NA

Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART

A NA study, sponsored by University of California, Davis.

Completed
Registry status
NA
Development phase
13
Enrollment target

NCT00386971: Completed NA study, sponsored by University of California, Davis.

NCT00386971 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00386971, a NA study, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target

Study Summary

Included in this study will be patients with HIV and being treated with highly active antiretroviral medications (HAART) including protease inhibitors (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI). Protease inhibitors and non-nucleoside reverse transcriptase inhibitors are very common medications in HIV treatment and are usually given with other medications as part of a standard treatment for HIV (HAART). We hope to learn more about how the levels of cholesterol-and triglyceride-carrying particles (lipoproteins) are affected by a nutritional supplement, L-Carnitine, in HIV-positive patients treated with antiretroviral medications.

Interventions

  • OTHER placebo
  • DIETARY_SUPPLEMENT L-carnitine

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2006-10
Est. Completion 2009-12
Phase NA
University of California, Davis

657 total trials

What the finished NCT00386971 record still lists

NCT00386971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00386971 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00386971 about?

NCT00386971 is a clinical study titled "Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART". Included in this study will be patients with HIV and being treated with highly active antiretroviral medications (HAART) including protease inhibitors (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI). Protease inhibitors and non-nucleoside reverse transcriptase inhibitors are very com...

What is the current status of trial NCT00386971?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2006-10. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00386971?

The interventions under investigation include: placebo (OTHER), L-carnitine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00386971?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00386971's enrollment target sits among peer trials

13 1911th of 2000 higher than 88 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00386971, the US trial registry maintained by the National Library of Medicine. NCT00386971 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.